Please ensure Javascript is enabled for purposes of website accessibility

Why Alexion Shares Popped

By Brian D. Pacampara, CFA - Apr 25, 2013 at 2:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is this meaningful? Or just another movement?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical company Alexion Pharmaceuticals (ALXN) climbed 10% today after its quarterly results and outlook topped Wall Street expectations.

So what: The stock was hammered in October on concerns over slowing growth, but a wide first-quarter beat -- adjusted EPS of $0.65 versus the consensus of $0.61 -- coupled with upbeat guidance, is quickly easing those concerns. In fact, sales of its key blood disorder drug Soliris spiked 38% to $338.9 million during the quarter, reigniting investor optimism over its mega blockbuster potential going forward.

Now what: Management now sees full-year adjusted EPS of $2.87-$2.97 on $1.51 billion-$1.52 billion, nicely above its prior view of $2.82-$2.92, and $1.49 billion-$1.51 billion. "The upward revision reflects continued global growth of Soliris in PNH and growth from the ongoing launch of Soliris in the US," said the company in a statement. More important, with the stock still off about 20% from its 52-week highs, biotech-savvy investors might have some room left to gain from that growth.

Interested in more info Alexion? Add it to your watchlist.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.